Switch theme
Sign up to access all valuation multiples
CurveBeam AI Ltd is a manufacturer of specialized imaging equipment that has developed software that, through the use of artificial intelligence (AI), and deep learning AI (DLAI), automates the scan processing and analysis of the high-quality images produced from the company’s CT devices to assist in the clinical assessment. The company has one operating segment, being the research, design, manufacture and sale of cone beam CT imaging equipment for orthopaedic specialties, which includes the development, validation and preparation for commercialisation of a HRpQCT Medical Device and Software as a Service (SaaS) platform.
2009
50
LTM Revenue $7.1M
LTM EBITDA -$8.7M
$24.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
CurveBeam AI has a last 12-month revenue (LTM) of $7.1M and a last 12-month EBITDA of -$8.7M.
In the most recent fiscal year, CurveBeam AI achieved revenue of $4.2M and an EBITDA of -$12.0M.
CurveBeam AI expects next 12-month revenue of XXX and NTM EBITDA of XXX
See CurveBeam AI valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $7.1M | XXX | $4.2M | XXX | XXX | XXX |
| Gross Profit | $4.1M | XXX | $1.9M | XXX | XXX | XXX |
| Gross Margin | 58% | XXX | 46% | XXX | XXX | XXX |
| EBITDA | -$8.7M | XXX | -$12.0M | XXX | XXX | XXX |
| EBITDA Margin | -122% | XXX | -285% | XXX | XXX | XXX |
| EBIT | -$11.4M | XXX | -$15.4M | XXX | XXX | XXX |
| EBIT Margin | -160% | XXX | -367% | XXX | XXX | XXX |
| Net Profit | -$12.1M | XXX | -$14.8M | XXX | XXX | XXX |
| Net Margin | -170% | XXX | -354% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $5.6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, CurveBeam AI's stock price is AUD 0 (or $0).
CurveBeam AI has current market cap of AUD 31.2M (or $20.1M), and EV of AUD 38.6M (or $24.8M).
See CurveBeam AI trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $24.8M | $20.1M | XXX | XXX | XXX | XXX | $-0.04 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, CurveBeam AI has market cap of $20.1M and EV of $24.8M.
CurveBeam AI's trades at 4.3x EV/Revenue multiple, and -2.4x EV/EBITDA.
Equity research analysts estimate CurveBeam AI's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
CurveBeam AI has a P/E ratio of -1.7x.
See valuation multiples for CurveBeam AI and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $20.1M | XXX | $20.1M | XXX | XXX | XXX |
| EV (current) | $24.8M | XXX | $24.8M | XXX | XXX | XXX |
| EV/Revenue | 3.5x | XXX | 4.3x | XXX | XXX | XXX |
| EV/EBITDA | -2.8x | XXX | -2.4x | XXX | XXX | XXX |
| EV/EBIT | -2.2x | XXX | -1.9x | XXX | XXX | XXX |
| EV/Gross Profit | 6.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.7x | XXX | -1.5x | XXX | XXX | XXX |
| EV/FCF | -3.2x | XXX | -2.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCurveBeam AI's last 12 month revenue growth is 128%
CurveBeam AI's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.3M for the same period.
CurveBeam AI's rule of 40 is -298% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
CurveBeam AI's rule of X is 197% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for CurveBeam AI and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 128% | XXX | 89% | XXX | XXX | XXX |
| EBITDA Margin | -122% | XXX | -177% | XXX | XXX | XXX |
| EBITDA Growth | -66% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -298% | XXX | -49% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 197% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 413% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CurveBeam AI acquired XXX companies to date.
Last acquisition by CurveBeam AI was XXXXXXXX, XXXXX XXXXX XXXXXX . CurveBeam AI acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was CurveBeam AI founded? | CurveBeam AI was founded in 2009. |
| Where is CurveBeam AI headquartered? | CurveBeam AI is headquartered in Australia. |
| How many employees does CurveBeam AI have? | As of today, CurveBeam AI has 50 employees. |
| Is CurveBeam AI publicy listed? | Yes, CurveBeam AI is a public company listed on ASX. |
| What is the stock symbol of CurveBeam AI? | CurveBeam AI trades under CVB ticker. |
| When did CurveBeam AI go public? | CurveBeam AI went public in 2023. |
| Who are competitors of CurveBeam AI? | Similar companies to CurveBeam AI include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, Cyclopharm, Healius. |
| What is the current market cap of CurveBeam AI? | CurveBeam AI's current market cap is $20.1M |
| What is the current revenue of CurveBeam AI? | CurveBeam AI's last 12 months revenue is $7.1M. |
| What is the current revenue growth of CurveBeam AI? | CurveBeam AI revenue growth (NTM/LTM) is 128%. |
| What is the current EV/Revenue multiple of CurveBeam AI? | Current revenue multiple of CurveBeam AI is 3.5x. |
| Is CurveBeam AI profitable? | Yes, CurveBeam AI is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of CurveBeam AI? | CurveBeam AI's last 12 months EBITDA is -$8.7M. |
| What is CurveBeam AI's EBITDA margin? | CurveBeam AI's last 12 months EBITDA margin is -122%. |
| What is the current EV/EBITDA multiple of CurveBeam AI? | Current EBITDA multiple of CurveBeam AI is -2.8x. |
| What is the current FCF of CurveBeam AI? | CurveBeam AI's last 12 months FCF is -$7.8M. |
| What is CurveBeam AI's FCF margin? | CurveBeam AI's last 12 months FCF margin is -109%. |
| What is the current EV/FCF multiple of CurveBeam AI? | Current FCF multiple of CurveBeam AI is -3.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
